Adcock Ingram’s Prescription sales increased by 4.1% to ZAR3.43bn ($191m) in its financial year ended 30 June 2024 – a year marred by a “significant amount of productional challenges,” including for Adcock’s key high-volume liquids facility in Clayville.
Adcock’s Annual Revenues Boosted By Higher Prices Amid Operational Challenges
Prescription Sales And Group Trading Profit Up 4%; Challenges In Clayville, Wadeville
South Africa’s Adcock Ingram welcomed 11 new product launches during its most recent financial year, as it battled on multiple fronts to maintain and ratchet up capacity at its local manufacturing facilities.
More from Earnings
• By
Partnering opportunities, paused marketing, approvals, litigations, and many more. Formycon sets out the agenda for 2025, after seeing a bumpy start to the year.
• By
Teva is charting a new course under its ‘Pivot to Growth’ strategy, providing a memory aid for investors to better understand the firm’s financials going into 2025.
• By
With sales and profits shooting up in 2024, Alvotech has revealed plans to rapidly accelerate development to add between four and six programs to its pipeline of biosimilars every year, while at the same time unveiling details of several new brands that it will be seeking to challenge. The firm has also set out longer-term financial targets that anticipate more than trebling its revenues in the next three years.
• By
The Chinese player reported its second profitable year in a row, with growth in sales reported across its marketed portfolio and further milestones in the near future.
More from Business
• By
Samsung Bioepis and Teva have provided clarity on the pricing of their Epysqli biosimilar to Soliris in the US, as the firms launched only the second rival to the rare diseases treatment.
• By
Teva is charting a new course under its ‘Pivot to Growth’ strategy, providing a memory aid for investors to better understand the firm’s financials going into 2025.
• By
Meitheal Pharmaceuticals said that its generic version of the GLP-1 agonist Victoza would be one of 22 planned launches during 2025, as the firm continues to build out its portfolio with the aid of its parent, Hong Kong King-Friend Industrial.